of recent studies have reponed progression of nephropa~ thy21-23 and retinopathYt l 4-12 and failure to improve neuropathyJ2 during insulin pump therapy, perhaps because metabolic control has not been sufficiently precise to reverse the diabetic lesions.
The development and progression of diabetic nephropathy have not been prevented by conventional treatment with insulin injections and diet. a -Io Nephropathy often develops in normal kidneys transplanted into diabetic recipients for end-stage renal failure, despite coneened efforts at metabolic control with conventional therapy.6l>-69 Our previous findings that whole pancreas transplantation is capable of preventing GBMT and ME. and our current demonstration that pancreaticoduodenal transplants are effective in preventing all rena} lesions of experimental DM, suggest that whole pancreas transplantation may be indicated in patients with end-stage diabeti<: nephropathy who require kidney transplantation and, therefore, must be given immunosuppression therapy for life. The outlook for the usefulness of pancreatic islet transplantation appears less promising.
A~1mowledRments
We thank Hazel J. SayeR .nd Sun Lee ror IfChnicalll$5iscance with the tm_anlalion operations. J am, at one point, however, concerned about the conclusions that Dr. Orloff has reached. Therefore, J would like to state a few facts and ask a couple of questions.
In 1974, in the journal Diabetes. we showed that syngeneic islets, when transplanted to rats, can prevent, as well as revene, the lesions of experimental diabetes in the kidney. This finding was reported in a syngeneic rat system in which the recipient rat was made diabetic with streptozotocin. a diff'erent form of bela cell poison than alloxan. This reversal was complete for diabetic lesions, which occurred within 3 months of streptozotocin treatment. However, if we waited 6-9 months, we could not reverse the lesions, which now became collagen-filled and irreversible. In its early and proliferative stages, however. the mesangial matrix material. which is the sine qua non of this lesion, could be reversed. In 1975, armed with this information, we progressed to treating 20 patients who were Type I diabetics with allogeneic islets. We transplan1ed them with what we believed were enough islets, and yet, in each instance, we were only able to reduce their insulin requirements but never cure a single patient (insulin independence).
We temporarily gave up on this technique and went back into the clinical arena to perform segmental organ transplantation of the pancreas, as we had done initially in 1966 with whole organ pancreaticoduodenal transplants. Since 1978, we have performed 185 segmental or whole organ pancreas transplants.
At the same time we were pllZZled with what happened to the transplanted islets in the previous clinical series. Was it a fact that we did not techoical1y transplant viable islets, or was the laclc of success due to immunologic rejection?
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To dctennine which phenomenon was responsible for this failure, we investigated a series of patients with chronic small duct pancreatitis.
We removed their pancreases. isolated the islets, and gave them back their own (autologous) islets, so there could be DO Orlolf that the most likely explanation for the vascular changes is the incomplete reversal of the metabolic state. But why? The pattern of failure suggests an inhospitable environment for the transplanted islets. Perhaps Dr. Orlolf could comment on the liver pathology, as alloxan produces periportal fibrosis, and this miaht interfere with islet function. These studies confinn that whole pancreas grafting is elfecti ve. and it results in byperinsulinemia. The eventual role of islet transplants, however, remains unanswered. DR. ROBERT J. CORRY (Iowa City, Iowa): I compliment Dr. Orlolf on an excellent paper reprding an important issue; that is whether or not successful pancreatic transplantation can prevent or stabilize the devastating secondary complications of Type I diabetes. In his study, rats who received islets did not achieve nonna! glucose control, suggesting either that an insufficient supply of islets was administered or something happened to them in the first few months, such that normal glucose control could not be achieved. On the other hand, whole orpn pancreatic transplantation resulted in normal glucose metabolism and prevented complications.
With regard to whole organ grafting we have reasons to be optimistic as a result of evidence emerging from a few U.S. and European pancreas transplant programs. In Stockholm. Carl Groth bas shown prevention of the mesangiaI thickening in the glomeruli in patients who recei~ combined kidney aod pancreas grafts compared with another group ofpa1ients transplanted at the same time, namely diabetic recipients whc) received kidneys only. AU patients who received ~neys and were followed after 3 years had microscopic changes of diabetes in the glomerulus, whereas none of the patients who received combined kidneys and pancreases bad any degree of mesanaiaI thickeniJIs. I would like to show a few slides indicating that wbole organ transplantation of the pancreas does not necessarily preclude successful liver donation. This illustration shows the blood supply ofbotb orpns dissected. Essentially the gastroduodenal artery is ligated and the splenic artery is divided a few millimeters from its origin on the hepatic artery. The superior mesenteric artery is divided near the pancreas.
The portal vein is divided IS it exits the pancreas. In this Way the blood supply for the donated liver will be normal, namely the aortic patch aod entire portal vein go with the liver. Extension grafts are placed on the pancreas under ice by taking a segment of donor iliac artery with both branches. The internal iliac artery is ~en joined to the superior mesenteric artery and the mernal iliac artery is joined to the splenic artery. Donor iliac vein is then used to extend the portal vein. These extension grafts are placed under iced solution so the ischemic time is not extended very much.
DR. THoMAS E. STAllZL (Pittsburgh, Pennsylvania): This is a grand organization that we belong to and the prestige of the organization is so IfCltt that a paper presented here is apt to be construed as the last word. If we really ~ this paper on absolutely face value. this could be the death koeO of islet ceD transplantation. It is in that context that I want to make a few comments and this is where I am inclined to be in agreement with Dr. Najarian.
Solid pancreas transplantation in principle as practiced successfully by Or. Orlolf and by others at Minnesota and elsewhere, is different than almost anything else we do. Ifwe transplant the kidney. there is no carrier tissue that comes along with the graft. It is a simple, straightforward intellectual exercise. If there is any carrier function that comes with the kidney, it might be the production of erythropoi&-tin. The bean is a simple pump. and with the liver, practically every cell does something that is essential for the survival and health of the recipient. In the case of the pancreas we are transplanting an organ in whi~h if we transplant 100 g, almost all of that is tissue, which, first of all, IS not needed, and second, is a nuisance. That extra tissue a<:COunts for almost all the morbidity and mortality of whole organ pancreas transplantation, which is consi~ble. What are the options? One of the options is the procedure that fared so poorly in Dr. Orloff's comparison. I do not doubt for a moment his conclusions, but I must say that I still have hopes for islet cell transplantation.1 hope that this paper, as fine IS it is, will not cause funding to be precluded for islet ceO research or elforts to be stopped by some of those groups that are still making those efforts such as Scharp in St. Louis, Lalferty and Wei! from Colorado, Mintz and Miller from Miami. and possibly others including Sutherland of Minnesota and Barker et aI. from Pennsylvania.
Other options have to be carefully explored because of the deficiencies not only of whole orpn transplantation, but also of islet cell transplantation. One possibility might weD be gene splicing, in which cells are endowed with the ability to produce insulin. Anything that could move us in that direction would be valuable and certainly would be worth pursuing.
The annals ofbistory, as my friend, Mark Ravitch. has reminded me often, are replete with missed opportunities. I could recount many but these would reveal my age. We do not have to go much farther back than last month's New England Journal 0/ Medici1U! in which there was a report from Mexico about succ;essful transplantation of adrenal tissue into the brain for the treatment of neuropsychiatric disorders. This was a procedure that bad been thoroughly discredited in previous Scandi-. ADa 
